• 12

• April

• 2024

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

LEARN MORE

• 04

• March

• 2024

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

LEARN MORE

• 28

• February

• 2024

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

LEARN MORE

• 21

• February

• 2024

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

LEARN MORE

• 02

• February

• 2024

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

LEARN MORE

• 01

• February

• 2024

Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference

LEARN MORE